Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2012

ROCKVILLE, Md., Feb. 8, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 14th Annual BIO CEO & Investor Conference 2012 in New York City on Monday, February 13, at 3:00 p.m. EST. Garr will present a business overview, and an update on the company's ongoing clinical trials in both its cell therapy and pharmaceutical divisions.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The webcast will be available in real-time at http://www.veracast.com/webcasts/bio/ceoinvestor2012/43114242.cfm, and again beginning one hour after the conclusion of the live event, and archived for 90 days. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com.

The BIO CEO & Investor Conference 2012 will be held at the Waldorf= Astoria in New York City, February 13-14. For more information, see: http://www.bio.org/events/conferences/14th-annual-bio-ceo-investor-conference. Now in its 14th year, the BIO CEO & Investor Conference is billed as the largest independent investor conference focused on publicly traded biotechnology companies.

Neuralstem's President and CEO Richard Garr is also scheduled to present at the 6th Annual BIO-Europe Spring Conference 2012, March 19-21, in Amsterdam, Holland. Please see http://www.ebdgroup.com/bes/index.php for more information.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

1 2 Next › Last »